Piclidenoson - Can-Fite Biopharma

Drug Profile

Piclidenoson - Can-Fite Biopharma

Alternative Names: CF-101; IB-MECA; SI-615

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Can-Fite BioPharma
  • Class Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Iodobenzenes; Neuroprotectants; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Apoptosis inhibitors; Immunosuppressants; Interleukin 17 receptor antagonists; Interleukin-23 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II/III Plaque psoriasis
  • Phase II Glaucoma
  • Phase I Uveitis
  • Preclinical Osteoarthritis
  • Discontinued Colorectal cancer; Dry eyes; Solid tumours

Most Recent Events

  • 17 Nov 2017 Can-Fite BioPharma terminates its licence to OphthaliX for piclidenoson in Opthalmic diseases
  • 01 Nov 2017 Piclidenoson is still in phase II development for Glaucoma (Monotherapy) in Bulgaria and Israel (NCT01033422)
  • 01 Nov 2017 Piclidenoson is still in phase II/III development for Plaque psoriasis (Monotherapy) in USA, Israel, Romania and Bulgaria (NCT01265667)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top